Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.